Primary analysis of phase 2 results with cemiplimab in metastatic basal cell carcinoma that is refractory to hedgehog pathway inhibitors Annals of Oncology Lewis, K. D., Peris, K., Sekulic, A., Stratigos, 1. j., Dunn, L., Eroglu, Z., Chang, A. S., et al 2023; Accepted